Zoetis (NYSE:ZTS) Given New $205.00 Price Target at Piper Sandler

Zoetis (NYSE:ZTS) had its price target increased by stock analysts at Piper Sandler from $200.00 to $205.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 24.25% from the stock’s current price.

Several other research firms have also weighed in on ZTS. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Barclays increased their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus price target of $215.90.

Zoetis Price Performance

ZTS stock opened at $164.99 on Thursday. Zoetis has a one year low of $144.80 and a one year high of $200.53. The firm has a 50-day moving average of $166.22 and a two-hundred day moving average of $177.58. The firm has a market capitalization of $73.88 billion, a PE ratio of 30.16, a P/E/G ratio of 2.78 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, analysts forecast that Zoetis will post 6.07 earnings per share for the current year.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zoetis

A number of institutional investors have recently made changes to their positions in ZTS. Mission Wealth Management LP increased its position in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares during the period. Hancock Whitney Corp raised its stake in Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after purchasing an additional 61 shares during the last quarter. Strategy Asset Managers LLC boosted its holdings in Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares during the period. VeraBank N.A. grew its position in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares during the last quarter. Finally, HUB Investment Partners LLC increased its holdings in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock worth $224,000 after purchasing an additional 62 shares during the period. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.